biotechnology 2009 india

8/8/2019 Biotechnology 2009 India

http://slidepdf.com/reader/full/biotechnology-2009-india 1/31

Download from: www.osec.ch

India

Biotechnology Industry

Compiled by

Swiss Business Hub India

October 2009



Download: www.osec.ch 3 / 31

Biotech Industry 2003-2007

0

200

400

600

800

1000

1200

1400

1600

1800

R

e v e n u e ( U S $ m i l l i o n

Bio-pharma 671 871 1148 1457 1683

Bio-services 67 104 176 269 383

Bio-agri 32 80 146 226 293

Bio-industry 58 78 91 96 100

Bio-informatics 20 24 29 35 46

2003-04 2004-05 2005-06 2006-07 2007-08

The bio-pharma is the industry's largest segment accounting for 67 per cent of the overall revenues, as per2007-08 data. The shares of other segments are: bio-services (15 percent), bio-agri (12 percent), bio-industrial(4 percent) and bio-informatics (2 percent). As mentioned above, this industry has a strong export linkage.

Biotech Industry- Exports Vs Domestic Sales 2007-08

37

366

976 707

7

12

9

93

281

17

0 200 400 600 800 1000 1200 1400 1600 1800

Bio-informatics

Bio-industrial

Bio-agri

Bio-services

Bio-pharma

US$ million

Exports Domestic

Source: India Brand Equity Foundation – IBEF / ABLE-Biospectrum Survey




The bio-pharma industry is accounted for largely by research, development and production of bio-similars orfollow-on biologics – copies of established biologic drugs. Gaining strength from the ongoing R&D, the bio-pharma segment is expected to reach US$ 5.5 billion by fiscal 2013. The total bio-pharma industry, consistingof therapeutics, vaccines, diagnostics, and other products such as statins, recorded a massive 26.9% growth infiscal year 2007 and continues to be largest contributor to the overall biotech market in the country. The goodperformance of the bio-pharma sector is attributed to the strongly growing vaccine business which accountedfor about 50% of the total bio-pharma business in fiscal year 2007. Interestingly, India is one of the largestproducers of traditional vaccines in the world. The producers of Hepatitis B vaccine continue to register robustgrowth, and more and more companies are focusing on under-served markets such as HIV, JapaneseEncephalitis and high-value combination vaccines. The vaccine business will remain dynamic in future, takingthe overall bio-pharma market up. Diagnostics and therapeutics businesses, which account for about 16

percent and 12 percent respectively of the bio-pharma market, are driven by a rise in chronic diseases andhuge investments being poured into the healthcare infrastructure with several path labs and hospitals openingup in India. The bio-pharma sector will further get a drive from the fact the India is forecasted to become a keybio-generics supplier to the developed world in near future. Notably, the top five players in bio-pharma segmenthave a 45 percent share of the market, and out of the top ten companies, seven are vaccine manufactures.

The following chart shows the prominence of bio-pharma segment in the total export of biotechproducts/services from India:

Share of different segments in biotech exports during 2007-08

70%

26%

1%1%

2%

Bio-pharma Bio-services Bio-agri Bio-industrial Bio-informatics

Source: Indian Brand Equity Foundation – IBEF / Biospectrum

As per a KPMG report, the Indian firms have a huge advantage over their counterparts in western marketsbecause of relatively lower R&D costs, so the industry can afford to be somewhat less risk-averse. Thecountry’s drug industry is building product capabilities in bio-similars, particularly in products such asrecombinant insulin, GCSF, interferon alpha, erythropoietin, and has started to move into monoclonal antibody(MAb) products and recombinant vaccines. Other fast growing areas include bio-engineering, which develops

new tissue engineering processes and biomaterials for therapeutics. India is also trying to play a prominent rolein the genomics space. The Indian genes have been mapped and now the country is moving towards open




source drug discovery. About INR 5 billion will be allocated for this, which is good for the industry and thesociety.

The Indian law allows stem cell research for therapeutic cloning, but prohibits reproductive cloning. The IndianCouncil of Medical Research and the Department of Biotechnology have laid down the Guidelines for Stem CellResearch and Therapy for adult, cord blood and embryonic stem cells in response to the support provided bythe Government to facilitate stem cell research in India so as to improve understanding of human health anddisease, and evolve strategies to treat serious diseases. The government plans include setting up an exclusivefund to support stem cell research in the country. There are also initiatives taken by the private sector to fosterresearch in this field. For example, the Reliance Life Sciences Institute has a good ranking amongst the topinstitutes worldwide working on stem cell research.

India shows promising potential and is fast becoming an important hub for outsourcing of clinical trials andcontract research. The key success factors for India are - a large pool of qualified scientists and engineers,institutional infrastructure, existing and upcoming cost-competitive research facilities, and a diversified patientpool. Besides this, the country also has diverse species of flora and fauna that give the added advantage forbiotech companies to carry on their research and drug discovery effectively. With the new legislation putting inplace a product patent regime post 2005, the business conditions for bio-services have been further improved.According to a report by RNCOS, the aforesaid factors would help India to increase its share in the globalclinical trials from less than 2 percent (2007) to 5 percent by 2012. The burgeoning clinical trials market in Indiais likely to create more business opportunities for a number of associated industries, including in vitrodiagnostics market, data management, as well.

India is ranked fourth in the world among Bt crops growing countries, in terms of cultivated hectares. The bio-agri is driven primarily by Bt cotton seeds, as these seeds market alone was estimated to be worth US$ 203

million last year. The bio-pesticides and bio-fertilizers estimated to have a combined market value of US$ 19.5million in the country, and among bio-fertilizers, phosphate-solubilising micro-organisms market witnessed thehighest growth. The country gave its nod for commercial cultivation of Bt cotton in early 2002. After six years, in2008, 30 seed companies were engaged in production of 274 Bt cotton hybrids. Growing manifold, the Btcotton acreage today accounts for about 80 per cent of the total area under cotton cultivation. Parallel with theintroduction of Bt cotton, the yield of cotton increased from 308 kg/ha in 2002 to 560 kg/ha in 2008 and isprojected to increase to 591 kg/ha in 2009. This has generated impressive economic gains for Indian farmersand enabled India to emerge as a net exporter of cotton from being a net importer. Remarkably, India emergedas the world’s second largest cotton producer in fiscal year 2007. According to a study report by Rabo IndiaFinance Limited Indeed, the country has the potential to also become a major producer of transgenic rice andseveral genetically modified (GM) or engineered vegetables. The research work is being carried in many crops.These include rice, cotton, eggplant, potato, tomato, corn, cabbage, castor, citrus fruit, black gram, andgroundnut. Bt. Brinjal (eggplant) is the first biotech vegetable food crop, which is under consideration of the

regulatory body for commercial approval in 2009. No doubt, the bio-agri continues to be one of the fastestgrowing segments in the overall biotech industry.

A diverse set of Indian companies is involved in the development of innovative technology in the bio-dieselarea, which is well supported by the government in order to decrease the reliance on imported fuel. India hasrecently initiated a Bio-fuel Policy which seeks to convert at least a major part of the 60 million hectares ofwastelands into farmlands for oil-bearing crops which can produce bio-diesel in plenty. There is no doubt thatthis policy will give further boost to the existing efforts by the private and public sector institutions to ensure thenation's energy security. The policy has set an ambitious target of 20 percent blended bio-diesel by 2017. Thismeans a production of 15-16 million tons of bio-diesel and a coverage area of over 30 million acres of bio-fuelplantation. Though the policy has been announced only less than a year ago, some companies, e.g. Reliance,have made significant investment in the bio-fuels arena by now.




The bioinformatics sector is successfully creating synergies between the IT and biotechnology industry.Certainly, the bioinformatics industry benefits from the strength of the IT industry in India. There are threedistinct kinds of bioinformatics companies in India now. Almost all the large IT services companies in Indiahave been looking at bioinformatics with interest from as early as the year 2001. The major Indian ITcompanies have large life sciences divisions. In terms of overall size, some estimates run close to $1 billion inbusiness that this segment generates for the IT services companies, although the actual bioinformatics contentof what many of these companies do is difficult to measure. A second group consists of companies that beganas start-ups a few years ago. Notably, some early bioinformatics companies have turned into broader contractresearch organizations and their bioinformatics business has become a minor part of their strategy. The third iscaptive bioinformatics groups within large pharmaceutical and biotechnology companies that use somebioinformatics for their research. Some of the big IT companies offer services relating to data mining, scientific

visualization, information storage or simulation of DNA sequences. The global bioinformatics market isexpected to grow at a CAGR of 16 per cent over 2007–10, whereas in India the growth is expected to be at ahigher rate - 25 percent. Though the Indian bioinformatics sector is growing rapidly, its share in the globalmarket is still miniscule. With a general revival of fortunes in the genomics, the business prospects for bio-informatics companies look good.

The bio-industry segment is concentrated with 70 percent of India’s enzyme market. There are some 15companies in India that are involved in the enzymes business. There are also players with focus on new areasof application, such as food processing, animal nutrition, dairy, aquaculture, marine etc. According to a Frost &Sullivan study, growing awareness and increased investments have led to the growth of biotechnologyapplications in the food and beverage and dietary supplements sector. The Indian food processing industry hasseen some promising product developments such as probiotic fortified yoghurt, buttermilk, omega fortifiedhealth drinks and baby foods. A lot more can be achieved through cutting edge R&D in the meadow ofbiotechnology resulting in innovative food and beverage products with improved functional and health benefit.

India’s top biotech companies as per the survey conducted by Biospectrum magazine and ABLE are asfollows:

Top 20 Biotech Companies (Revenue-wise)

Rank2008

Company 2007-08Revenue( INR mio).

2006-07Revenue (INR mio.)

Y-o-YGrowth

1. Serum Institute of India 9870.00 9509.50 4%2. Biocon 9120.00 8490.00 7%3. Panacea Biotec 6779.80 7011.30 -3%4. Nuziveedu Seeds 3030.00 2264.20 33.8%5. Rasi Seeds 2932.80 3333.30 -12%6. Novo Nordisk 2600.00 2220.00 17%7. Novozymes South Asia 2250.00 1000.00 125%8. Indian Immunologicals 1960.00 1579.00 24%9. Mahyco 1700.00 1106.90 54%10. Syngene International 1600.00 1320.00 21%11. Jubilant 1590.00 - -12. Shantha Biotechnics 1500.00 1150.00 30%13. Bharat Serums 1400.00 1084.90 29%14. Eli Lilly 1370.00 1140.00 20%15. Bharat Biotech 1260.00 700.00 80%

16. Themis Medicare 1100.00 680.00 62%17. Aventis 1050.00 1196.50 -12%




18. Haffkine Biopharma 886.10 656.90 35%19. Rossari Biotech 820.00 660.00 24%20. GlaxoSmithKline 804.00 790.00 2%

Industry’s Overall Revenue 102737.00 85410.00 20%

Exchange rate: 1 USD = 41 INR

India has a number of biotech clusters, and these are located mainly in Bangalore (Karnataka), Pune-Mumbai(Maharashtra), Hyderabad (Andhra Pradesh), NCR Delhi, and Ahmedabad-Vadodara (Gujarat). The othermajor locations for biotech industry include Kolkata and Lucknow. Bangalore has the largest number of biotechcompanies in the country. Hyderabad has witnessed a lot of infrastructural development in the biotech domainwherein a Knowledge Park, Biotech Park, Genome Valley and other projects are operational giving this city anadvantage over many others. As the government has adopted a proactive policy on setting up of industry-specific special economic zones, many public and private enterprises are in the process to set up new biotechzones/parks in the country.

The industry is now aiming to achieve a revenue of $5 billion by 2010. This optimistic outlook has its roots inforeign companies increasingly investing in India. According to industry players, escalating research anddevelopment expenses and stringent policies are making manufacturers from the regulated markets looktowards India for cutting costs. A Frost and Sullivan report says that multinational pharmaceutical andbiotechnology companies from western Europe and the US are using India and China for their phased studieson emerging markets. Besides, cheaper clinical trials and extra benefits, such as availability of good technicalabilities, are boosting foreign investments, says the report. The pharmaceutical manufacturing hubs such asDelhi, Mumbai, Chennai, Ahmedabad, Hyderabad and Bangalore are fast improving their abilities to provideenhanced collaborative and outsourced R&D services. Currently, such services include drug discovery andvalidation processes, and, in the fields of pathway analysis (study of effect of toxic or radioactive substances on

humans), genomics (study of gene sequences), proteomics (study of proteins) and translational research(investigation and experiments on patients and volunteers). In this context, Kiran Mazumdar-Shaw,Chairperson and Managing Director, Biocon group, a leading biotech company, has said, "Co-developmentagreements are leading to interesting models." Many leading Indian biotech companies have entered intocollaborative arrangements with overseas companies, such as Merck & Company, GSK, Eli Lilly, Bristol MyersSquibb, and Ortho-McNeil Janssen.

Over the last few years, Asia, and more so India, has been a high growth market for the global life sciencesuppliers. Almost all the global majors like Agilent Technologies, Bio-Rad, GE Healthcare, Invitrogen, Millipore,Pall, Perkin Elmer, Shimadzu, Thermo Electron, and Waters Corporation have strengthened their presence andmarket hold in India. These global companies are consolidating their presence in India for two main reasons.One, growing Indian market has become more important for foreign companies. The other reason is toleverage the skilled manpower in terms of R&D activities in India. The demand for all the products - separation,

instrumentation, mass spectrometry, surface sciences, lab automation, or general lab equipment - is on the risemainly from the generic drug manufacturers and contract research organizations. With strong growth in R&Dand production, the bio-supplier industry is also on a robust growth path, almost 30 percent growth annually.

Some of the developments in recent times bear testimony to the robust growth momentum in Indian biotechindustry:

• According to a report released by Med Ad News last year, Biocon had found a place amongst top 25biotechnology companies worldwide. Biocon Limited was the only Asian company to feature in thisranking at number 20. The companies were ranked according to their revenues.

• Serum Institute of India is possibly the world’s largest vaccine manufacturer of measles and DTPvaccines.

•

Biocon is the largest manufacturer of insulin in Asia.




• Asia's first and the world's second human DNA bank has been set up at the Biotech Park in India (UttarPradesh State). The members of the DNA bank will receive a microchip-based DNA card containinginformation of their fingerprints, and anthropological details.

• Biovel, an integrated biotechnology firm, launched Asia's first Bio Safety Level-4 (BSL-4)manufacturing facility, specifically designed to facilitate product development and manufacturing ofvaccines like Foot and Mouth Disease vaccine (FMD).

3. Potential Growth of the Biotechnology Industry

According to a report jointly prepared by the Confederation of Indian Industry (CII) and KPMG some time back,the Indian biotechnology sector has excellent potential and is expected to touch US $5 billion mark by 2010. No

doubt this sector, like many other sectors, is feeling the impact of the present global economic slowdown.Therefore, attaining the US$ 5 billion mark may not be so easy now.

Nevertheless, the following factors will be driving the growth: Growing population and improving incomes Emerging lifestyle diseases Increasing investment in infrastructure and R&D, both by public and private sectors Increasing outsourcing opportunities in the manufacturing Emerging contract research market

The bio-pharma segment is expected to continue its dominance in the overall Indian market. The vaccinemanufacturers will certainly be the leading force. With respect to diagnostics, many products are beingimported into the country, but at the same time there is a new competitiveness emerging from the local players.

Furthermore, the therapeutics remain the thrust in Indian R&D, with human insulin being the most commonarea of research. The reason is that India has over 37.5 million people suffering from diabetes and the numberis rising. India has 25 per cent of the world’s haemophiliac population, therefore plasma proteins is anemerging market here. The country has been sourcing plasma proteins from MNCs such as Baxter, and nodoubt there is good potential for manufacturing plasma proteins locally and indigenously. MonoclonalAntibodies (mAbs) are also a fast-growing market especially in oncology and auto-immune diseases.Furthermore, India has 3 million cancer patients and 700,000 new cases are added every year, that is whymore and more Indian companies are looking for collaborations with foreign companies in this field. Indian bio-pharma companies are also looking to compete in the space of New Biological Entities and make them a keysource of growth in the long term. They are exploring partnership models such as joint product developmentand joint marketing to build a distinguished presence in this segment.

Bio-agri is also developing quite well in India. The country is the second largest food producer after China and

therefore, offers enormous opportunities for transgenic crops. The usage of Bt cotton has made a remarkableimpact on the farming community. The Indian farmer has been quick (than what was perceived earlier) to adoptnew technology as he could see real value in it. The commercial approval of more transgenic plants is likely topush further growth in this segment. According to an analysis, if bio-fertilizers were used to substitute 25percent of chemical fertilizers on 50 percent of India’s crop, the market potential would be 235 thousand MT,compared to only 13 thousand MT now. Also, the bio-pesticides are expected to grow at an annual rate of 10-15 percent in the short term.

Similarly, the business prospects in bio-services, bio-informatics, and bio-industrial are enormous as Indiacontinues to offer cost-competitive “eco system” for biotech companies. In bio-industrial area, the segments likeindustrial enzymes and renewable energy hold good business prospects.




4. Government Initiatives

The Indian government has been consistently endeavouring to provide and foster an environment conducive tobiotech development since 1986. The government approved a national biotechnology development strategylast year. It was an outcome of a long nationwide consultation process involving multiple stakeholders. A keyelement of the strategy is the setting up of a National Biotechnology Regulatory Authority (NBRA). This willprovide a single window biosafety clearance of genetically modified products/processes. This is something thatthe industry has been demanding for a long time as, without such an institution, the release of biotech productsinto the Indian market gets unduly delayed. Presently, a draft bill for the establishment of NBRA is beingcirculated for inter-ministerial consultation.

The Department of Biotechnology is pushing for increasing public-private partnerships in research anddevelopment. DBT has earmarked 30 per cent of its budget for such collaborative research. The governmenthas also launched a Biotechnology Industry Partnership Programme (BIPP) and a Biotechnology IndustryResearch Assistance Programme (BIRAP). These schemes are one of the most enabling mechanisms topromote biotech industry R&D and public private partnership programmes. The government aims to supportthe industry also by expanding the pool of researchers, creating a higher quality technical workforce, andcreating industrial platforms, that can eventually build sustainable growth for the biotech sector. Establishingpartnerships with key foreign countries active in biotech is also a remarkable initiative by the Indiangovernment. This has been helping the country to adopt the best practices out of the shared experiences,thereby improving the R&D infrastructure.

The government is trying to boost the sector by facilitating requisite infrastructure in terms of biotech parks

(some examples are TICEL Bio Park in Hyderabad, Tidel Park in Chennai) and Special Economic Zones.Some new technology clusters are being planned in the various fields of biotechnology. For example,discussions are being held to set up a biotechnology cluster in the University of Agricultural Sciences,Bangalore campus close to National Centre for Biological Sciences. The government has also initiated aproject to conduct genome-wide research on a range of agronomically important crops.

In order to facilitate foreign direct investment in the biotechnology sector, all project proposals exceeding FDI ofUS $ 22 million, are handled by the Department of Biotechnology (DBT)’s Fast track Committee. The DBT hasalso taken initiatives to link 63 bioinformatics centres in India to promote networking of information resources.The availability of funds for DBT has been drastically increased by the government. During the current 5-yearPlan (2007-2012), the biotechnology sector receives government funding amounting to INR 65 billion ascompared to INR 14.5 billion in the previous 5-year Plan.

The followings are some of the incentives being offered generally by the Indian government to thebiotechnology sector:

Allows Income Tax benefit - weighted deduction of 150% for R&D expenditure as well as oninternational patenting costs until 2012.

Offers exemption/concession on import duties on specified items for R&D and clinical trial equipment. Offers Service tax exemption on clinical trials of new drugs including vaccines and herbal remedies. Considering biotechnology for priority sector lending, the government encourages banks to lend money

to biotech companies. Offers Excise duty and Sales tax exemption for bio-diesel. Offers tax benefits to Venture Capitalists investing in biotech industry. Offers support for industry research under the “New Millennium India Technology Leadership Initiative

(NMITLI)”. It has been launched to catalyze innovation oriented scientific and technologicaldevelopments in selected niche areas by synergizing the best competencies of publicly funded R&Dinstitutions, academia and private industry. Two broad categories of projects are supported under




NMITLI – nationally evolved projects and industry originated projects. Financial support will be providedunder NMITLI in the form of Grants-in-Aid to institutional partners in public domain and as soft loan.

With its Small Business Innovation Research Initiative (SBIRI) for a small and medium business unit(the company should have a well established in-house R&D unit with not more than 500 employeesand recognized by Department of Scientific and Industrial Research), the government offers analternative financing possibility for biotech start ups. Generally and subject to fulfilment of the termsand conditions laid down by the Department of Biotechnology, a start-up is provided up to a maximumof US$ 100,000 as a grant in a first phase to enable the company to undertake innovative pre-proof-of-concept research and late stage development and commercialization of the innovation research.Further financial assistance is offered as soft loan carrying interest rates ranging from 1-2 percent.Furthermore, the advanced companies are offered equity financing through the SME Growth Fund ofSmall Industries.

The Ministry of Science and Technology is promoting a number of centres of excellence for

biotechnology. These institutes with state-of the art technology and highly skilled labour collaboratewith the private industry.

5. Conclusions

India is already globally recognised as a manufacturer of economical, high quality bulk drugs and formulations.The opportunities in the bio-pharma segment are promising. For example, the bio-pharma companies arealready playing an important role in the global vaccines market. With many more innovative indigenousrecombinant therapeutic products in the pipeline, and with USFDA-compliant facilities, the business prospectslook quite bright. With regard to clinical trials, India offers many advantages in this particular space, and that iswhy it is able to create a win-win situation for more collaboration with foreign companies. Furthermore, theglobal evolution of the genomics business in areas such as “Next Generation Sequencing” and “ConsumerGenomics” etc., in the coming future holds good business potential for bio-informatics companies in India.

Overall, with a large base of skilled and cost competitive scientific manpower, easy availability of raw materialsuch as plants and animals, and human genetic diversity, and a well-developing scientific infrastructure with abig network of research laboratories, India has potential to gradually become a leading global player inbiotechnology. The setting up of a biotech regulator and more positive evolution of the intellectual propertyregime in the country can further help in increasing India’s share in the global biotech industry.

The Indian biotech companies do look out to have access to the latest technology from the developed countriesas well as to the marketing support in the foreign markets. Indian researchers need to partner with qualityresearchers from developed countries as such shared experiences often lead to adoption of best practices. Anumber of bilateral programmes are already under implementation to promote such collaborations between

Indian and foreign companies/institutions.

It goes without saying that there is good scope for Swiss companies to explore collaboration with Indiancompanies or set up their own R&D centres in India, that complement their business models and provide cost-competitive quality infrastructure needed to achieve/enhance competitiveness in the fast moving globalisationof businesses. Some Swiss biotech companies, e.g. Evolva, RCC Pharma, Roche, and Syngenta are alreadyfunctional in India, whereas Indian companies, such as Dr. Reddy’s Laboratories, Biocon, and DivisLaboratories have their presence in Switzerland.




6. Important Contacts

Department of Biotechnology (DBT): http://dbtindia.nic.in/index.asp Department of Science and Technology (DST): http://dst.gov.in Association of Biotechnology Led Enterprises (ABLE): http://www.ableindia.org India Brand Equity Foundation (IBEF): http://www.ibef.org Bio Spectrum Magazine: http://biospectrumindia.ciol.com

Date: 14th

October, 2009

Author: Mohinder NayyarAuthor’s Address: Swiss Business Hub India

Embassy of SwitzerlandNyaya Marg, Chankayapuri,New Delhi 110 021Tel: 0091 11 26878372E-mail: [email protected]

Encl: A select list of India’s 100 Biotech Companies




A Select List of India’s 100 Biotech Companies

ABL Biotechnologies LtdNo.55, Third East Street,Kamaraj Nagar, Tiruvanmiyur,Chennai600 041Tel: 044 42020501/ 42020502.Fax: 044 42020957E-mail : [email protected] http://www.ablbiotechnologies.com

Accutest Research Lab (I) Pvt. Ltd.A-31, TTC Industrial AreaKhairane MIDC, Thane Belapur RoadNavi Mumbai400 709Tel: 022 2778 0718 / 19 / 20Fax: 022 2778 0721

E-mail: [email protected] www.accutestindia.com

Acton Biotech (India) Pvt. Ltd4

thFloor, Banoo Coyaji Building

KEM Hospital

RastapethPune411 011Tel: 020 3231 9395-2605 1094Email: [email protected]

Advanced Enzyme Technologies Ltd'A' Wing, Sun Magnetica,5th Floor, Accolade Galaxy,LIC Service Road, Louisewadi,Thane400 604.

Tel: 022-2583 8350 –54Fax: 022-25835159.Email: [email protected]://www.enzymeindia.com

Advinus Therapeutics Pvt. Ltd.Quantum TowersPlot No 9, Rajiv Gandhi Infotech Park, Phase – IHinjewadiPune411 057Tel: 020 6653 9600Fax: 020 6653 9620

E-mail: [email protected]




Aptuit Laurus Private Limited2nd Floor, Serene ChambersRoad # 7, Banjara HillsHyderabad500 034Tel: 040 3980 4333-2342 0500Fax: 040 23420 503Email: [email protected]

Asiatic Clinical Research Pvt. Ltd.169/53, 14th Main Road

1st Block EastJayanagarBangalore560 011Tel : 080 4168 1122 / 33 / 44Fax : 080 4121 3841Email: [email protected]

Aurigene Discovery Technologies Limited39-40, KIADB Industrial AreaElectronic City Phase II, Hosur RoadBangalore

560 100Tel: 080 2852 1314 - 1316 - 8943Fax: 080 2852 6285E-mail: [email protected] www.aurigene.com

Avesthagen LimitedDiscoverer, 9th FloorInternational Technology ParkWhitefield RoadBangalore560 066Tel: 080-2841 1665/2308/2770/2766

Fax: 080-2841 8780E-mail: [email protected]

AVT BiotechnologyPlot No. 66, Kinfra Export Promotion Industrial Parks LtdKusumagiri P.OCochin682 030Tel: 0484-2415177-2415178-2413177Fax: 0484-2415179E-mail : [email protected] http://www.avtbiotech.com/




Bangalore Biotech Labs Pvt. Ltd.# 49/2, Gubbi Cross, Off Hennur CrossHennur - Bagalur Road, KothanurBangalore560 077Tel: 080 6530 9009-9006Fax: 080 2846 5668E-mail: [email protected] www.biozeen.com

Bangalore Genei6, VI Main, BDA Industrial SuburbNear SRS Road, Peenya

Bangalore560 058Tel: 080 2839 1453 / 6894 / 2837 8057Fax: 080 2839 2825E-mail: [email protected] www.bangaloregenei.com

Bharat Biotech International Ltd.Genome Valley, ShameerpetHyderabad500 078Tel: 040 2348 0567-2875 7836Fax: 040 2348 0560

Email: [email protected] www.bharatbiotech.com

Bharat Serums and Vaccines Ltd.Hoechst House, 16th FloorNariman PointMumbai400 021Tel: 022 6656 0900Fax: 022 6656 0901E-mail : [email protected]

Bhat Bio-tech India (P) Ltd.11-A, 4th CrossVeerasandra Industrial AreaElectronics CityBangalore560 100Tel: 080 4351 4000Fax: 080 4351 4001E-mail: [email protected] www.bhatbiotech.com




Bi Biotech328, Ansal Chamber II6 Bhikaji Cama PlaceNew Delhi110 066Tel: 011 2610 1271Fax: 011 2610 1273E-mail : [email protected] www.biotechindia.com

Bigtec Private Limited#100/1, 3rd Floor, Anchorage-1,Richmond Road,

Bangalore560 025Tel: 080 4001 9999Email: [email protected] http://www.bigtec.co.in

BioCin Bioproducts Pvt. Ltd.401 Shanti Soudha ErramanzilHyderabad500 082Tel: 040 23316288E-mail: [email protected]://www.biocin.com

Biocon India20th KM, Hosur RoadElectronics CityBangalore560 100Tel: 080 2808 2808Fax: 080 2852 3423Email: [email protected]

Bioserve Clinical Research Pvt Ltd6-56/6/1A, Opp: IDPL

NH9, BalanagarHyderabad500 037Tel: 040 2377 0873 - 74Fax: 040 2377 0877E-mail: [email protected] www.bioserve.co.in




Biovel Life Sciences (P) LimitedSy.No.16, EkarajapuraHasigala (Post), Sidlagatta RoadHosakoteBangalore562 114Tel: 080-27971111Fax: 080-27971121E-mail : [email protected] www.biovel.net

Caliber Technologies Pvt. Ltd.

401, 406, Bhanu Enclave, Model ColonyHyderabad500038Tel: 040-23811322Fax: 040-23817922Email: [email protected] http://www.caliberindia.com

Camson Bio Technologies Ltd.No.223, 1st MainDomlur 2nd StageBangalore560 071

Tel: 080 2535 5138Fax: 080 2535 2232E-mail: [email protected] www.camsonbiotechnologies.com

Celestial Labs LimitedPlot No: 231/A, Road No.12,MLA Colony, Banjara Hills,Hyderabad500034Tel: 040 2354 0008Fax: 040 2354 2844E-mail: [email protected]

http://www.celestiallabs.com

ChembiotekBlock BN, Sector VSalt Lake CityKolkata700 091Tel: 033 2367 3151 - 52 - 53Fax: 033 2367 3058www.chembiotek.com




Concord Biotech Limited302, Sakar III,Opp. Old Gujarat High Court,Off. ITO Circle,Ahmedabad380 014.Tel: 079 27544998 / 27543557Fax: 079 27540802E-mail: [email protected] http://www.concordbiotech.com

Connexios Life Science Pvt. Ltd.

#49, Shilpa VidyaFirst Main Road, JP Nagar 3rd PhaseBangalore560 078Tel : 080 4121 0672 - 587 - 5491 -92Fax : 080 4121 0705E-mail: [email protected] http://www.connexios.com/

Dr. Reddy’s Laboratories Ltd.GreenlandsAmeerpetHyderabad

500 016Tel: 040 2373 1946 /7/8/9/50Fax: 040 2373 1955Email: [email protected]

DSS Imagetech Pvt. Ltd.A-5 Mohan Co-op Indl. EstateMathura RoadNew Delhi110044Tel: 011-30886715 / 17 / 35 / 66Fax: 011-26959382

http://www.dssimage.com

Fermenta Biotech Limited DIL Complex,Ghodbunder Road,Thane (West)400 610Tel. : 022 6798 0888Fax : 022 6798 0999Email : [email protected]://www.fermentabiotech.com




Fortune Biotech Ltd.6-6-125, KavadigudaSecunderabad500380Tel: 040-27531726Fax: 040-27536089E-mail: [email protected]://www.fortunebiotech.com

Frontier Tissueline(Bio-science unit of Frontier Lifeline)R-30-C Ambattur Industrial

Estate Road,Mogappair,Chennai600 101Tel: 044 42017575, 26564224E-mail: [email protected] http://www.frontierlifeline.com/

GangaGen Biotechnologies Pvt Ltd.No 12, 5th Cross, Raghavendra LayoutOpposite MEI Ltd,Tumkur RoadYeshwanthpur

Bangalore560 022Tel: 080 4062 1300 to 4062 1328Fax: 080 4062 1329E-mail: [email protected] www.gangagen.com

Genetix Biotech Asia Pvt. Ltd71/1, Shivaji Marg,New Delhi110 015.Tel: 011-4502-70000Fax: 011-2541-9631

E-mail: [email protected] http://www.genetixbiotech.com

Genotex International# 4B, S.P.Biotech ParkTurkapalli Village,Shameerpet Mandal, R.R.DistrictAndhra PradeshTel: 040.22373438, Mo.: 98492 03303E-mail: [email protected]://www.genotex.net




High-tech Agri Services# 490, 5th Cross, 5th Main,2nd block, R.T.Nagar,Bangalore560032Tel: 080 - 23634371Fax : 080-41697171E-Mail: [email protected]://www.hightechagri.com

Hindustan Bio Sciences Limited Plot No. 31, Street No. 2, Sagar Society,Road No. 2, Banjara Hills,

Hyderabad.Tel: 040 23555161, 5171.Fax: 040 2354 9411Email: [email protected]

H.U. Gugle Biotech Pvt. LtdNo. 23, P.O. Box No. 14,Binnamangala Village,Devanahalli Taluk,Bangalore Dist.562 110Tel: 080 768 0669 / / 080 5760 9502

E-mail: [email protected]://www.hugugle.com

Imperial Life Sciences (P) Limited463 Pace City II, Sector - 37,Gurgaon122 001Tel: 0124 - 4559800 - 99Fax 0124 - 4559801E - mail : [email protected] http://www.imperialls.com

Indian Immunologicals Ltd.

Road # 44, Jubilee HillsHyderabad500 033Tel: 040 2354 4585 - 4593Fax: 040 23544007www.indimmune.com

Indigene Pharmaceuticals, Pvt. Ltd.Indigene HouseRoad No. 14, Banjara HillsHyderabad500 034Tel: 040 2348 7000

Fax: 040 2354 8478http://www.indigenepharma.com




IndovaxCorporate Heights,SCO - 24, Sector - 14,Gurgaon122001

Tel.: 0124-2315044 / 45 / 46Fax : 0124-2314680E-mail: [email protected] http://www.indovax.com

Indus Biotech Private Limited India1 Rahul Residency,

Off Salunke Vihar Road,KondhwaPune411048Tel: 020 6478 5063/63Fax: 020 2685 0039E-mail: [email protected]

http://www.indusbiotech.com

Intas Biopharmaceuticals Ltd.Plot No. 423 / P / A/ GIDCSarkhej - Bavla Highway,Moraiya, Taluka - Sanand,

Ahmedabad,382 210Tel: 02717 - 660100/01Fax : 02717 – 251189E-mail: [email protected]://www.intasbiopharma.co.in

International Panaacea LimitedE-34, Connaught Circus,New Delhi110 001Tel: 011-23418880-86Fax: 11-23418889


J.K. Agri Genetics Limited1-10-177, 4th floor, Varun TowersBegumpet,Hyderabad500 016Tel: 040 66316858Fax: 040 27764943E-mail: [email protected] http://jkseeds.net




Jubilant Organosys1A, Sector 16ANOIDA201 301Tel: 0120-2516601-11Fax: 0120-2516628-30http://www.jubl.com/

Kaypeeyes Biotech Pvt. Ltd.306-C, Hebbal Industrial AreaMetagalli PostMysore570 016

Tel: 0821 528 0039Fax: 0821 240 3694Email: [email protected] www.kpsbio.com

Lifecare Innovations Pvt. Ltd.B-589, Sushant Lok Phase - I,Gurgaon122 002,Tel: 0124-4041932,Fax: 0124-4041933,Email: [email protected] http://www.lifecareinnovations.com/home.htm

Lumis Biotech Ltd.501, Arun Chambers,Tardeo,Mumbai400034Tel: 022 66662690 / 91 / 92 / 93 / 94Fax: 022 23515034E-mail: [email protected]://www.lumisbiotech.com

Maharashtra Hybrid Seed Company,

Dawalwadi,

PO Box 76,Jalna,431203 Tel: 02482-233881, 233882Fax: 02482-262002E-mail: [email protected] http://www.mahyco.com




Maps (India) Limited302, Shapath-3,Near GNFC Info Tower,S.G. Road,Ahmedabad380054.India.Tel: 079 26859971-74Fax: 079) 26859975E-mail: [email protected]://www.mapsenzymes.com

Max Neeman InternationalMax House, GF-1Dr. Jha MargOkhlaNew Delhi110 020Tel: 011 2632 2816 - 2632 2824Fax: 011 26322846http://www.neeman-medical.com/

Metahelix Life Sciences Pvt LtdPlot No. 3, KIADB, 4th PhaseBommasandra

Bangalore560 099Tel: 08110 - 414555Fax: 08110- 415074E-mail: [email protected] www.meta-helix.com

MGL758, 1st FloorUdyog Vihar, Phase – 5Gurgaon122016Tel: 0124 – 4505360

Fax: 0124 – 4505299http://www.mgl.com

Microbax (India) Limited3-6-108/1, Liberty RoadHimayat NagarHyderabad500 029Tel: 040 55360055Fax: 040 55360057E-mail: [email protected] www.microbax.com




Molecular Connections Private LimitedKandala Mansions, # 2/2, Kariappa Road,Basavanagudi,Bangalore560 004Tel: 080 4120 5016Fax: 080 4120 8956E-mail: [email protected]://www.molecularconnections.com

Multiplex Bio-Tech Pvt. Ltd.No. 180, 1st Main Road,Mahalakshmi Layout,

Bangalore560 086Tel : 080-2349 7464/2349 4406Fax : 080-2349 0647E-mail: [email protected]://www.multiplexgroup.com

Namdhari Seeds Pvt. LimitedBidadiBangalore,562109Tel: 9845471271/ 9845471272/ 9845381817Fax: 080-28602168

E-Mail: [email protected]://www.namdhariseeds.com

Nuziveedu Seeds LimitedNSL ICON,4 th FloorRoad No: 12Banjara HillsHyderabad500 034Tel: 040-3051 4444Fax: 040 2332 7919E-mail: [email protected]

Ocimum Biosolutions6th Floor, Reliance ClassicRoad No. 1Banjara HillsHyderabad500 034Tel: 040 6698 6700Fax: 040 6662 7205E-mail:[email protected] www.ocimumbio.com




Organica Biotech Pvt. Ltd.36, Ujagar Industrial EstateW.T. Patil MargGovandiMumbai400 088Tel: 022 6797 5150Fax: 022 6797 5149E-mail: [email protected]://www.organicabiotech.com/

Panacea Biotec Ltd.B-1 Extn./ A-27

Mohan Co-op. Industrial EstateMathura RoadNew Delhi110 044Tel: 011-41578021Fax: 011-41679060E-mail: [email protected] www.panaceabiotec.com

Piramal Healthcare Ltd.1st floor, D - Mart BuildingGoregaon Mulund Link RdMulund West

Mumbai400 080Tel: 022 3953 6666E-mail: [email protected]

Polyclone Bio Services Pvt. Ltd.# 47, 4th Main, 25 th CrossKaresandra, Banashankari, 2nd StageBangalore560 070Tel: 080 2671 7181Fax: 080 2671 4849

E-mail: [email protected] www.polyclonebio.com

PREMAS Biotech Pvt. Ltd., Plot No. 77, Sector 4,IMT Manesar,Gurgaon122050,Tel: 0124-4546600Fax: 0124-4365221Email: [email protected]://www.premasbiotech.com




Proalgen Biotech Limited#15, III Avenue, Indra NagarAdyar,Chennai600 020Tel: 044 - 2445 4332Fax: 044 - 2445 4756E-mail: [email protected]://www.proalgenbiotech.com

Rasi Seeds (P) Ltd273, Kamarajanar RoadP.O. Box No: 30

Attur636 102Tel: 04282-241007, 242007Fax: 04282-242558E-mail: [email protected]://www.rasiseeds.com/

Reliance Life Sciences, Biotechnology DivisionR-282, TTC Industrial Area of MIDC,Thane-Belapur Road, Rabale,Navi Mumbai400 701

Tel: 022 4067 8000Fax: 022 4067 8099E-mail: [email protected] http://www.rellife.com

RFCL LimitedA-3, Okhla Industrial Area, Phase-INew Delhi110 020Tel: 011 42395700 (Direct), 41609171-75 (Board)Fax : 011 41609189E-mail : [email protected]://www.rfcl.in

Richcore Lifesciences Pvt. Ltd#168, Sri SapthagiriIst Floor, II nd Main Road, East of N.G.E.FKasturinagarBangalore560 043Tel: 080 4044 7474Fax: 080 4044 7484Email :[email protected] www.richcoreindia.com




Rossari Biotech401, Omega, Main Street,Hiranandani Gardens,Powai,Mumbai400 076Tel :: 022-25709200 / 01E-mail: [email protected] www.rossari.com

Serum Institute of India Ltd.212/2 Hadapsaroff Soli Poonawalla Road

Pune411 028Tel: 020 2699 3900Fax: 020 2699 3921E-mail: [email protected] www.seruminstitute.com

Spinco Biotech4, Vaidyaram Street, T.Nagar,Chennai600 017Tel: 044 2434 0174Fax: 044 2434 0761

E-mail: [email protected] http://www.spincotech.com

Sri Biotech Laboratories India Limited#211, Bhavya’s Sree Arcade,Bata Complex, Erragadda,Hyderabad500 018.Tel : 040-23702823, 23701153E-mail-: [email protected]://www.sribio.com

Strand Life Sciences

237 Sir C.V. Raman AvenueRajmahal Vilas, SadashivnagarBangalore560 080Tel: 080 4078 7263Fax: 080 2361 8996http://www.strandgenomics.com/




Sun Agro Biosystem Private Ltd3/340, Main Road,Madanandapuram, Porur,Chennai600 116Tel: 044 – 2482 7652 / 6984Fax: 044 – 2482 7998Email: [email protected]://www.sunagrobiosystem.com

Sungro Seeds Limited3d floor,Sungro Camber,B.N. Block,

Local Shopping Center,Shalimar Bagh,Delhi110088Tel : 011-27471117, 27488272Fax : 011-27470333Email : [email protected]://www.sungroseeds.com

Synergy Biotechnologies #1-58, Snehapuri, Nacharam,Hyderabad500 076

Tel: 040-27174095Fax: 040-27176365E-mail: [email protected]://www.synergybiotech.net

Syngene International Ltd.Biocon Park , Plot 2&3,Bommasandra Industrial Estate - Phase-IVBommasandra-Jigani Link Road,Bangalore560 099Tel: 080 2808 2808Fax: 080 2808 3150

E-mail: [email protected] http://www.syngeneintl.com

Tex Biosciences Pvt. Ltd. "Textan House" 75, Fourth Avenue,Ashok NagarChennai600 083Tel : 044-42988700Fax : 044-42988787E-mail : [email protected]




Themis Medicare Ltd.11/12, Udyog NagarS.V.Road, Goregaon WestMumbai400 104Tel: 022 6760 7080Fax: 022 2874 6621www.themismedicare.com

Torrent Gujarat Biotech LimitedTorrent House,Off Ashram Road,Ahmedabad

380 009Tel: 079 2658 5090,2658 3060Fax: 079 2658 2100Email: [email protected]://www.torrentlimited.com/tgbl.htm

Unique Biotech LimitedPlot No. 123, Phase-V, I.D.A.JeedimetlaHyderabad500 055Tel: 040 2319 3092Fax: 040 2309 3089


VARDA Biotech (P) Ltd.#110 & 111, Kartik complexNew Link RoadAndheri WestMumbai400 053Tel: 022 6693 5686-2673 0141-2673 4258Fax: 022 6693 5687www.vardabiotech.com

Venkateshwara HatcheriesVenkateshwara House, S.No. 114/A/2,Pune-Sinhagad Road, Viththalwadi,Pune411 030Tel: 020-24251530 to 41Fax: 020-24251077E-mail: [email protected]://www.venkys.com



VINS Bioproducts Ltd.806, Essjay House,Road No.: 3,Banjara Hills,Hyderabad500 034Tel: 040-23354550, 23353540, 55622962Fax: 040-23350410E-mail: [email protected] www.vinsbio.in

VLife Sciences Technologies

Pride Purple Coronet287 Vibhag 39/563, Baner Road,Pune411 045Tel: 020 2729 1590Fax: 020 2729 1591E-mail: [email protected] http://www.vlifesciences.com

Yash Medicare Private Limited,Nr. Sabar Dairy, Talod Road,PO. Hajipur,Himatnagar, Gujarat

383 006Tel : 02772-226 099Fax: 02772-229 399Email: [email protected]://www.ympl.net

biotechnology 2009 india

Documents